Medical Cannabis for Older Patients—Treatment Protocol and Initial Results

  title={Medical Cannabis for Older Patients—Treatment Protocol and Initial Results},
  author={Ran Abuhasira and Addie Ron and Inbal Sikorin and Victor Novack},
  journal={Journal of Clinical Medicine},
Older adults may benefit from cannabis treatment for various symptoms such as chronic pain, sleep difficulties, and others, that are not adequately controlled with evidence-based therapies. However, currently, there is a dearth of evidence about the efficacy and safety of cannabis treatment for these patients. This article aims to present a pragmatic treatment protocol for medical cannabis in older adults. We followed consecutive patients above 65 years of age prospectively who were treated… 

Figures and Tables from this paper

Cannabis Use in Older Adults: A Perspective
Special considerations pertinent to older adults are reviewed, specifically, the impact of cannabis on cognition and on falls and injuries, its drug interactions, and its potential medicinal applications for treating the behavioral and psychological symptoms of dementia.
Medical cannabinoids for treatment of neuropsychiatric symptoms in dementia: a systematic review
Most studies indicated that use of medical cannabinoids engendered favorable outcomes for treatment of NPS related to moderate and advanced stages of dementia, particularly agitation, aggressive behavior, sleep disorder, and sexual disinhibition.
Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: May 2021 Update
This report describes the cumulative literature identified thus far in patients with chronic (mainly neuropathic) pain with short-term treatment and concludes that whole-plant cannabis, low THC to CBD ratio products, and comparisons with other active interventions was insufficient to draw conclusions.
Cannabis Use and Misuse in Older Adults.
A Clinical Framework for Assessing Cannabis-Related Impairment Risk
A practical framework is presented for clinicians to assess and stratify cannabis-associated impairment risk, intended to practically guide healthcare providers in gaining a more comprehensive review of a patient's impairment-related factors.
Safety and Tolerability of Natural and Synthetic Cannabinoids in Older Adults: A Systematic Review and Meta-Analysis of Open-Label Trials and Observational Studies
A meta-analysis of open-label observational studies of cannabinoid-based medications for all indications in individuals with a mean age of ≥50 years found cannabinoids were generally safe and acceptable to adults aged over 50 years.
Cannabis use frequency, route of administration, and co-use with alcohol among older adults in Washington state
In a general population representative sample of adults living in a state with legal adult use cannabis, the prevalence of cannabis use increased among those aged 50–64 between 2014 and 2016, the likelihood of daily use is substantial, and oral administration and vaping are increasing.
Safety and tolerability of natural and synthetic cannabinoids in adults aged over 50 years: A systematic review and meta-analysis
This pooled analysis, using data from RCTs with mean participant age ≥50 years, suggests that although THC-containing CBMs are associated with side effects, CBMs in general are safe and acceptable in older adults.


Medical Cannabis in Parkinson Disease: Real-Life Patients' Experience
Medical cannabis was found to improve symptoms of PD in the initial stages of treatment and did not cause major adverse effects in this pilot, 2-center, retrospective survey.
Medical Cannabis for Older Patients
A pragmatic clinical approach to a rational dialogue with older patients is proposed, highlighting the importance of individual benefit–risk assessment and shared patient–clinician decision making.
Overview of persistent pain in older adults.
A broad overview of the scope and impact of persistent pain in older people and mechanisms by which persistent geriatric pain can lead to suffering and disability is provided.
Cannabis for dyskinesia in Parkinson disease
Orally administered cannabis extract resulted in no objective or subjective improvement in dyskinesias or parkinsonism in Parkinson disease patients.
Dronabinol for the treatment of agitation and aggressive behavior in acutely hospitalized severely demented patients with noncognitive behavioral symptoms.
The Increasing Use of Cannabis Among Older Americans: A Public Health Crisis or Viable Policy Alternative?
This essay reviews trends concerning cannabis use and applies the age-period-cohort paradigm to explicate varied pathways and outcomes, and turns to how cannabis may be a viable policy alternative in terms of supporting the health and well-being of a substantial number of aging Americans.
Demographic trends among older cannabis users in the United States, 2006–13
The prevalence of cannabis use has increased significantly in recent years among US adults aged ≥ 50 years and older, and past-year users were more likely to be younger, male, non-Hispanic, not have multiple chronic conditions and use tobacco, alcohol or other drugs compared with non-past-year cannabis users.
Weighing the Evidence: A Systematic Review on Long-Term Neurocognitive Effects of Cannabis Use in Abstinent Adolescents and Adults
Findings are mixed regarding impairments in inhibition, impulsivity and decision making for CU, but there is a trend towards worse performance, and heavy use is found to be more consistently associated with effects in diverse domains than early age of onset.